Samsung Biologics Says PolyPeptide Tender Offer Draws 97.98% Stake

PUBT · 1d ago
Samsung Biologics Says PolyPeptide Tender Offer Draws 97.98% Stake
  • Samsung Biologics disclosed in a Nov. 6, 2026 correction that its PolyPeptide Group tender offer secured 97.98%, representing 32,350,302 shares.
  • The company plans to reach 100% ownership through measures including a compulsory acquisition of remaining minority stakes under Swiss law.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung Biologics Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261106000001), on November 06, 2026, and is solely responsible for the information contained therein.